Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
13.1M
-
Shares change
-
+2.15M
-
Total reported value, excl. options
-
$341M
-
Value change
-
+$56.1M
-
Number of buys
-
36
-
Number of sells
-
-19
-
Price
-
$26.06
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q3 2019
68 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2019.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.1M shares
of 45.1M outstanding shares and own 29.05% of the company stock.
Largest 10 shareholders include Sofinnova Investments, Inc. (2.1M shares), FMR LLC (1.63M shares), BlackRock Inc. (1.32M shares), Cormorant Asset Management, LP (884K shares), PERCEPTIVE ADVISORS LLC (855K shares), PRICE T ROWE ASSOCIATES INC /MD/ (838K shares), ALLIANCEBERNSTEIN L.P. (766K shares), VANGUARD GROUP INC (743K shares), WELLINGTON MANAGEMENT GROUP LLP (411K shares), and Artal Group S.A. (400K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.